{"id":923468,"date":"2026-01-05T07:21:12","date_gmt":"2026-01-05T12:21:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-u-s-prevent-trial\/"},"modified":"2026-01-05T07:21:12","modified_gmt":"2026-01-05T12:21:12","slug":"bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-u-s-prevent-trial","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-u-s-prevent-trial\/","title":{"rendered":"BD Marks Milestone with First Phasix\u2122 Hernia Prevention Case in Greece and Over 85% Enrollment in U.S. PREVENT Trial"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\">FRANKLIN LAKES, N.J.<\/span>, <span class=\"legendSpanClass\">Jan. 5, 2026<\/span> \/PRNewswire\/ &#8212;\u00a0BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced a significant milestone in its advanced tissue regeneration strategy: the first Phasix\u2122 Mesh laparotomy reinforcement case performed in Greece following the product&#8217;s expanded indication for prophylactic use in Europe. This marks the first broad prophylactic indication of hernia mesh across open, high-risk procedures in the European Union.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/2854126\/BD_PREVENT_Trial_Milestone.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/2854126\/BD_PREVENT_Trial_Milestone.jpg\" title=\"BD Marks Milestone with First Phasix\u2122 Hernia Prevention Case in Greece and Over 85% Enrollment in U.S. PREVENT Trial\" alt=\"BD Marks Milestone with First Phasix\u2122 Hernia Prevention Case in Greece and Over 85% Enrollment in U.S. PREVENT Trial\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>The procedure was completed at George Papanikolaou General Hospital of Thessaloniki, one of the largest institutions in northern Greece, led by general surgeon and Associate Professor, Ioannidis Orestis. The patient, a 63-year-old male with multiple risk factors, underwent a sigmoidectomy, and a Phasix\u2122 Mesh (08 x 30 cm) was placed prophylactically at the laparotomy incision site to reduce the likelihood of future hernia development.<\/p>\n<p>Concurrently, BD&#8217;s PREVENT multicenter randomized controlled trial, conducted across sites in both Europe and the United States, has treated over 85% of its target population and is projected to complete enrollment in 2026. The study aims to provide robust clinical evidence supporting prophylactic bioabsorbable mesh placement to reduce the incidence of incisional hernias, while also supporting PMA submission for an incisional hernia prevention indication in the United States.<\/p>\n<p>&#8220;Incisional hernias affect up to 30% of patients after abdominal surgery and cost health care systems billions annually,&#8221; said Rian Seger, worldwide president of the BD Surgery business. &#8220;With Phasix\u2122 Mesh, we&#8217;re not just repairing hernias\u2014we&#8217;re preventing them. This milestone reflects our commitment to improving long-term patient outcomes.&#8221;<\/p>\n<p>According to recent U.K. data, patients who undergo incisional hernia repair incur an average cost of \u00a323,148\u2014nearly double that of patients who do not require repair. Prevention strategies have the potential to significantly reduce these costs and improve patient quality of life.<\/p>\n<p>Phasix\u2122 Mesh received CE marking approval for the prophylactic indication and launched three new sizes in 2025. The product is now registered in the U.K. and available across Europe for broad hernia prophylaxis indications, marking a pivotal step toward redefining surgical best practices, helping clinicians deliver safer outcomes and improve efficiency in every procedure. <b>Phasix\u2122 Mesh is not indicated for use for hernia prevention in the United States.<\/b><\/p>\n<p>\n        <b>About\u00a0BD<\/b>\n      <\/p>\n<p>BD is\u00a0one of the\u00a0largest global medical\u00a0technology\u00a0companies\u00a0in the\u00a0world\u00a0and is\u00a0advancing\u00a0the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians&#8217; care delivery process, enable laboratory scientists to accurately detect disease and advance researchers&#8217; capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in\u00a0virtually\u00a0every\u00a0country\u00a0and\u00a0partners\u00a0with\u00a0organizations\u00a0around\u00a0the\u00a0world to\u00a0address\u00a0some\u00a0of the\u00a0most\u00a0challenging\u00a0global\u00a0health issues.\u00a0By\u00a0working in\u00a0close\u00a0collaboration\u00a0with\u00a0customers,\u00a0BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit <u><a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4588707-1&amp;h=908172440&amp;u=http%3A%2F%2Fwww.bd.com%2F&amp;a=bd.com\" target=\"_blank\" rel=\"nofollow\">bd.com<\/a><\/u>\u00a0or connect with us on LinkedIn at <u><a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4588707-1&amp;h=1418873908&amp;u=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fbd1%2F&amp;a=www.linkedin.com%2Fcompany%2Fbd1%2F\" target=\"_blank\" rel=\"nofollow\">www.linkedin.com\/company\/bd1\/<\/a><\/u>, X (formerly Twitter) <u><a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4588707-1&amp;h=3625876398&amp;u=https%3A%2F%2Ftwitter.com%2Fbdandco&amp;a=%40BDandCo\" target=\"_blank\" rel=\"nofollow\">@BDandCo<\/a><\/u>\u00a0or Instagram <u><a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4588707-1&amp;h=420362438&amp;u=https%3A%2F%2Finstagram.com%2Fbecton_dickinson%3Figshid%3DOGQ5ZDc2ODk2ZA%253D%253D&amp;a=%40becton_dickinson\" target=\"_blank\" rel=\"nofollow\">@becton_dickinson<\/a><\/u><\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Contacts:<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n              \n            <\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <u>Media<\/u><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <u>Investors<\/u><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Fallon McLoughlin<br \/>Director,\u00a0Public Relations<br \/>201.258.0361\u00a0 <br \/><u><a href=\"mailto:Fallon.Mcloughlin@bd.com\" target=\"_blank\" class=\"prnews_a\" rel=\"nofollow\">Fallon.Mcloughlin@bd.com<\/a><\/u> \u00a0<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Adam Reiffe <\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Vice President, Investor Relations<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">201.847.6927\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <u><br \/>\n                    <a href=\"mailto:mailto:adam.reiffe@bd.com\" target=\"_blank\" class=\"prnews_a\" rel=\"nofollow\">Adam.Reiffe@bd.com<\/a><br \/>\n                  <\/u>\u00a0 <\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1479210\/BD_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1479210\/BD_Logo.jpg\" title=\"BD (Becton, Dickinson and Company) Logo (PRNewsfoto\/BD (Becton, Dickinson and Company))\" alt=\"BD (Becton, Dickinson and Company) Logo (PRNewsfoto\/BD (Becton, Dickinson and Company))\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=NY55965&amp;sd=2026-01-05\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-us-prevent-trial-302652279.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-us-prevent-trial-302652279.html<\/a><\/p>\n<p>SOURCE BD (Becton, Dickinson and Company)<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY55965&amp;Transmission_Id=202601050650PR_NEWS_USPR_____NY55965&amp;DateId=20260105\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire FRANKLIN LAKES, N.J., Jan. 5, 2026 \/PRNewswire\/ &#8212;\u00a0BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced a significant milestone in its advanced tissue regeneration strategy: the first Phasix\u2122 Mesh laparotomy reinforcement case performed in Greece following the product&#8217;s expanded indication for prophylactic use in Europe. This marks the first broad prophylactic indication of hernia mesh across open, high-risk procedures in the European Union. The procedure was completed at George Papanikolaou General Hospital of Thessaloniki, one of the largest institutions in northern Greece, led by general surgeon and Associate Professor, Ioannidis Orestis. The patient, a 63-year-old male with multiple risk factors, underwent a sigmoidectomy, and a Phasix\u2122 Mesh (08 x 30 cm) was placed &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-u-s-prevent-trial\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BD Marks Milestone with First Phasix\u2122 Hernia Prevention Case in Greece and Over 85% Enrollment in U.S. PREVENT Trial&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-923468","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BD Marks Milestone with First Phasix\u2122 Hernia Prevention Case in Greece and Over 85% Enrollment in U.S. PREVENT Trial - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-u-s-prevent-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BD Marks Milestone with First Phasix\u2122 Hernia Prevention Case in Greece and Over 85% Enrollment in U.S. PREVENT Trial - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire FRANKLIN LAKES, N.J., Jan. 5, 2026 \/PRNewswire\/ &#8212;\u00a0BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced a significant milestone in its advanced tissue regeneration strategy: the first Phasix\u2122 Mesh laparotomy reinforcement case performed in Greece following the product&#8217;s expanded indication for prophylactic use in Europe. This marks the first broad prophylactic indication of hernia mesh across open, high-risk procedures in the European Union. The procedure was completed at George Papanikolaou General Hospital of Thessaloniki, one of the largest institutions in northern Greece, led by general surgeon and Associate Professor, Ioannidis Orestis. The patient, a 63-year-old male with multiple risk factors, underwent a sigmoidectomy, and a Phasix\u2122 Mesh (08 x 30 cm) was placed &hellip; Continue reading &quot;BD Marks Milestone with First Phasix\u2122 Hernia Prevention Case in Greece and Over 85% Enrollment in U.S. PREVENT Trial&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-u-s-prevent-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-05T12:21:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2854126\/BD_PREVENT_Trial_Milestone.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-u-s-prevent-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-u-s-prevent-trial\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BD Marks Milestone with First Phasix\u2122 Hernia Prevention Case in Greece and Over 85% Enrollment in U.S. PREVENT Trial\",\"datePublished\":\"2026-01-05T12:21:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-u-s-prevent-trial\\\/\"},\"wordCount\":603,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-u-s-prevent-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2854126\\\/BD_PREVENT_Trial_Milestone.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-u-s-prevent-trial\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-u-s-prevent-trial\\\/\",\"name\":\"BD Marks Milestone with First Phasix\u2122 Hernia Prevention Case in Greece and Over 85% Enrollment in U.S. PREVENT Trial - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-u-s-prevent-trial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-u-s-prevent-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2854126\\\/BD_PREVENT_Trial_Milestone.jpg\",\"datePublished\":\"2026-01-05T12:21:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-u-s-prevent-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-u-s-prevent-trial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-u-s-prevent-trial\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2854126\\\/BD_PREVENT_Trial_Milestone.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2854126\\\/BD_PREVENT_Trial_Milestone.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-u-s-prevent-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BD Marks Milestone with First Phasix\u2122 Hernia Prevention Case in Greece and Over 85% Enrollment in U.S. PREVENT Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BD Marks Milestone with First Phasix\u2122 Hernia Prevention Case in Greece and Over 85% Enrollment in U.S. PREVENT Trial - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-u-s-prevent-trial\/","og_locale":"en_US","og_type":"article","og_title":"BD Marks Milestone with First Phasix\u2122 Hernia Prevention Case in Greece and Over 85% Enrollment in U.S. PREVENT Trial - Market Newsdesk","og_description":"PR Newswire FRANKLIN LAKES, N.J., Jan. 5, 2026 \/PRNewswire\/ &#8212;\u00a0BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced a significant milestone in its advanced tissue regeneration strategy: the first Phasix\u2122 Mesh laparotomy reinforcement case performed in Greece following the product&#8217;s expanded indication for prophylactic use in Europe. This marks the first broad prophylactic indication of hernia mesh across open, high-risk procedures in the European Union. The procedure was completed at George Papanikolaou General Hospital of Thessaloniki, one of the largest institutions in northern Greece, led by general surgeon and Associate Professor, Ioannidis Orestis. The patient, a 63-year-old male with multiple risk factors, underwent a sigmoidectomy, and a Phasix\u2122 Mesh (08 x 30 cm) was placed &hellip; Continue reading \"BD Marks Milestone with First Phasix\u2122 Hernia Prevention Case in Greece and Over 85% Enrollment in U.S. PREVENT Trial\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-u-s-prevent-trial\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-05T12:21:12+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2854126\/BD_PREVENT_Trial_Milestone.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-u-s-prevent-trial\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-u-s-prevent-trial\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BD Marks Milestone with First Phasix\u2122 Hernia Prevention Case in Greece and Over 85% Enrollment in U.S. PREVENT Trial","datePublished":"2026-01-05T12:21:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-u-s-prevent-trial\/"},"wordCount":603,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-u-s-prevent-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2854126\/BD_PREVENT_Trial_Milestone.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-u-s-prevent-trial\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-u-s-prevent-trial\/","name":"BD Marks Milestone with First Phasix\u2122 Hernia Prevention Case in Greece and Over 85% Enrollment in U.S. PREVENT Trial - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-u-s-prevent-trial\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-u-s-prevent-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2854126\/BD_PREVENT_Trial_Milestone.jpg","datePublished":"2026-01-05T12:21:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-u-s-prevent-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-u-s-prevent-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-u-s-prevent-trial\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2854126\/BD_PREVENT_Trial_Milestone.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2854126\/BD_PREVENT_Trial_Milestone.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bd-marks-milestone-with-first-phasix-hernia-prevention-case-in-greece-and-over-85-enrollment-in-u-s-prevent-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BD Marks Milestone with First Phasix\u2122 Hernia Prevention Case in Greece and Over 85% Enrollment in U.S. PREVENT Trial"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/923468","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=923468"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/923468\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=923468"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=923468"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=923468"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}